<DOC>
	<DOCNO>NCT00957658</DOCNO>
	<brief_summary>The purpose study evaluate clinical radiographic outcome data patient implanted Accolade® TMZF® femoral stem .</brief_summary>
	<brief_title>Accolade® TMZF® Hip Stem Outcomes Study</brief_title>
	<detailed_description>A prospective , post-market , multi-centered clinical evaluation Accolade® TMZF® hip stem device . All patient enrol receive study device . All study patient undergo preoperative central Dual energy X-ray absorptiometry ( DXA ) scan determine bone mineral density ( BMD ) value .</detailed_description>
	<criteria>1 . Patient candidate primary total hip replacement . 2 . Patient primary diagnosis osteoarthritis ( OA ) . 3 . Male nonpregnant female patient age 18 90 . 4 . Patient sign Institutional Review Board ( IRB ) approve , study specific Informed Patient Consent Form . 5 . Patient willing able comply postoperative schedule clinical radiographic evaluation rehabilitation . 6 . Patient capable undergoing preop central DXA ( dualenergy xray absorptiometry ) scan bone mineral density ( BMD ) reading . 1 . Patient active infection within affected hip joint . 2 . Patient require revision surgery previously implant total hip arthroplasty hip fusion affect joint . 3 . Patient morbidly obese , Body Mass Index ( BMI ) &gt; 40 . 4 . Patient neuromuscular neurosensory deficiency , limit ability evaluate safety efficacy device . 5 . Patient follow diagnosed systemic disease : Paget 's disease , renal osteodystrophy , lupus erythematosus , rheumatoid arthritis , metabolic bone disease sickle cell anemia . 6 . Patient immunologically suppress receive chronic steroid 30 day . Patients receive oral IV steroid within one month surgery . 7 . Patient prisoner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Osteoarthritis</keyword>
</DOC>